Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
01349
Company Profile
Business description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
Contact
308 Cailun Road
Zhangjiang Hi-Tech Park
Pudong
Shanghai201210
CHNT: +86 2158953355
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
876
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.
stocks
What did Morningstar subscribers buy and sell in April?
How the most traded shares in April stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,873.50 | 43.80 | -0.49% |
| CAC 40 | 8,082.27 | 0.00 | 0.00% |
| DAX 40 | 24,456.26 | 319.45 | 1.32% |
| Dow JONES (US) | 50,063.46 | 370.26 | 0.75% |
| FTSE 100 | 10,372.93 | 47.58 | 0.46% |
| HKSE | 26,124.13 | 264.91 | -1.00% |
| NASDAQ | 26,635.22 | 232.88 | 0.88% |
| Nikkei 225 | 61,849.81 | 804.24 | -1.28% |
| NZX 50 Index | 12,918.04 | 107.03 | -0.82% |
| S&P 500 | 7,501.24 | 56.99 | 0.77% |
| S&P/ASX 200 | 8,631.50 | 42.00 | -0.48% |
| SSE Composite Index | 4,165.55 | 12.37 | -0.30% |